Published review highlights Hippo-YAP/TAZ pathway as therapeutic target for brain aging

A newly published scientific review highlights the Hippo-YAP/TAZ signaling pathway as a central regulator of brain aging and neurodegeneration, suggesting its potential as a novel disease-modifying therapeutic target.

A scientific review published in Biogerontology outlines the physiological and pathological roles of the Hippo-YAP/TAZ signaling pathway in the aging brain.

The authors detail how dysregulation of Hippo signaling leads to cellular senescence, impaired synaptic plasticity, blood-brain barrier disruption, and neurodegeneration.

The paper emphasizes the pathway's extensive crosstalk with other critical mechanisms, such as autophagy, mitochondrial homeostasis, and neuroinflammation, and discusses potential small-molecule modulators and drug-repurposing candidates.

Current treatments for neurodegenerative diseases remain primarily symptomatic, highlighting the critical need for upstream, disease-modifying targets.

Because the Hippo-YAP/TAZ pathway sits at the intersection of multiple cellular stress responses, targeting it could address several hallmarks of brain aging simultaneously.

Its role in maintaining neural stem cells and promoting neuronal survival makes it an attractive node for regenerative medicine approaches in neurology.

While therapeutic development targeting the Hippo pathway in the central nervous system is in its infancy, this review provides a biological foundation that could drive future drug discovery programs.

The identified crosstalk between Hippo signaling and established aging hallmarks like autophagy and inflammation may open new avenues for biotechnology companies already targeting these specific mechanisms.

Preclinical studies evaluating the safety and efficacy of specific small-molecule Hippo-YAP/TAZ modulators in animal models of age-related neurodegenerative diseases.